News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Microsulis Medical Limited Sells Microwave Endometrial Ablation (MEA) to Hologic, Inc. (HOLX)



2/7/2011 7:24:59 AM

DENMEAD, England--(BUSINESS WIRE)-- Microsulis Medical Limited (http://www.microsulis.com/) announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From 2007 Microsulis has focused strategically on the development of its breakthrough microwave tumour ablation MTA system. “Following years of investment and technical development in 2010 we achieved CE Mark and FDA 510k clearance on our revolutionary high power Microwave Tumour Ablation (MTA) system. This breakthrough system redefines the performance benchmark for tumour ablation devices in the interventional oncology market. Through the sale of our MEA platform to Hologic, we not only open our microwave technology to the most capable device developer in the woman’s health space, but we release the value of MEA to underpin the commercialization phase of our MTA device.” commented Microsulis CEO Stuart McIntyre. “Hologic has the capability and market leadership needed to release the potential of our microwave technology to treat various female urological and gynecological conditions. There is no better company to nurture the technology in the woman’s health space.”

Hologic is the leading supplier of medical devices and products for treating women’s health conditions. The NovaSure Endometrial Ablation System is recognized worldwide as a premier product with a long track record of safety and efficacy. “We look forward to working with Hologic over the next months and years in developing value from our technology portfolio. We are pleased that our customers will continue to be supported by such a capable company.” said Stuart McIntyre.

About Microsulis Medical Limited

Founded in 1997, Microsulis Medical Ltd is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic devices. The company was initially formed following research collaboration between Chemring and the University of Bath in 1993. The company leads the field in microwave technology for endometrial ablation, tumour ablation, and venous occlusion. For more information on Microsulis Medical Limited please visit www.microsulis.com.

Contact:

Schwartz Communications, Inc. for Microsulis Charlotte Webber +44 (0)7949 872296 Microsulis@schwartz-pr.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES